Unlocking the Potential of Genetic Medicines

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

Johnson & Johnson Robotics and Digital Solutions

Ridgeback Capital

BioMotiv

Biotechnology Value Fund

BVF Partners

HealthCap

Ionis Pharmaceuticals

Northpond Ventures

Cowen Healthcare Investments

Johnson & Johnson Innovation – JJDC

Aro Biotherapeutics

We are excited for the opportunity to present at the 20th Annual WORLD Symposium 2024 meeting!

We are excited to announce we have secured our Series B financing!

https://lnkd.in/d_znquZc

We are excited to announce our transition to a clinical stage company with the start of our first in human trial of ABX1100, a Centyrin-siRNA conjugate in development for Pompe Disease

#Centyrin #siRNA #PompeDisease #RareDisease

https://lnkd.in/erdkqrKz

Biotechnology company focusing on autoimmune disease therapies

Athos Therapeutics

Biotechnology company specializing in genetic medicines

Kyverna

Biotechnology company involved in protein drug platform development

GRI Bio

Biotechnology company with a focus on innovative therapies

Creative BioLabs

Company specializing in genetic medicines

TetraGenetics Inc

Aro Biotherapeutics is a biotechnology company based in Philadelphia, pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is focused on developing a pipeline of Centyrin-based therapeutic candidates and working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 5, 2024 10:42 AM	7cebb87c
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 10:42 AM	8873c4e4
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	993048b7
crunchbase profile	general
li profile	general	Mar 5, 2024 10:42 AM	7e17bb27
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 5, 2024 10:42 AM	ebd9ef04
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AROBIOTX

Aro Biotherapeutics